A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer.
Ratio Therapeutics’ Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.
Company Details
- Employees
- 64
- Founded
- 2021
- Address
- 1 Design Center Pl,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://ratiotx.com/
- HQ
- Boston, Massachusetts
Ratio Therapeutics Questions
Ratio Therapeutics's website is https://ratiotx.com/
Ratio Therapeutics's LinkedIn profile is https://www.linkedin.com/company/ratio-therapeutics
Ratio Therapeutics has
64 employees.
View email and phone details for 64
employees at Ratio Therapeutics.
Ratio Therapeutics's industry is
Biotechnology Research
Ratio Therapeutics's top competitors are
Rayzebio,
Fusion Pharmaceuticals,
Clarity Pharmaceuticals,
Mariana Oncology,
Aktis Oncology,
Lantheus,
Nucleus Radiopharma,
Syndax Pharmaceuticals,
Telix Pharmaceuticals Limited,
Kura Oncology, Inc..
Ratio Therapeutics's categories are Biotechnology Research
Ratio Therapeutics's founding year is 2021
